

17th June 2022

- | | |
|---|--|
| <p>(1) BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> <p>Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> <p>Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Sub: Intimation under Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby notify that Cipla has entered into definitive agreements on 17th June 2022 for the acquisition of 21.05% stake (on a fully diluted basis) in Achira Labs Private Limited.

Requisite details under SEBI Listing Regulations, 2015 read with Circular No. CIR/CFD/CMD/4/2015 dated 9th September 2015 are enclosed as Annexure – I to this letter.

Kindly acknowledge receipt.

Thanking you,
Yours faithfully,
For Cipla Limited


Rajendra Chopra
Company Secretary



Encl: Details as per the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Prepared by: Simona Dsouza

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

Annexure – I

Details as per the SEBI circular no. CIR/CFD/CMD/4/2015 dated 9th September 2015

Sr. No.	Particulars	Details
a)	Name of the target entity, details in brief such as size, turnover etc.;	<p>Name of the target entity: Achira Labs Private Limited (hereinafter referred to as “Achira”)</p> <p>Brief details: Achira is a point-of-care (“PoC”) diagnostic company incorporated under the provisions of Companies Act, 1956. It is engaged in the business of the development and commercialization of innovative technologies for PoC medical testing.</p> <p>Turnover: Rs. 13.79 crores (unaudited) as on 31st March 2022.</p>
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	<p>Acquisition does not fall within the purview of related party transactions.</p> <p>None of the promoter/promoter group/group companies have any interest in the entity.</p>
c)	Industry to which the entity being acquired belongs;	Healthcare Industry: Engaged in development and commercialisation of PoC medical test kits.
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	<p>Investment in Achira will enable Cipla to enter into the business domain of designing, developing and manufacturing microfluidics-based PoC immunoassay and molecular assay technologies.</p> <p>Post-acquisition, Achira will become an associate of Cipla Limited.</p>
e)	Brief details of any governmental or regulatory approvals required for the acquisition;	Not Applicable.
f)	Indicative time-period for completion of the acquisition;	The transaction is expected to be complete within 60 days from the signing of definitive agreements or such other date mutually agreed between the parties and shall be subject to conditions precedent as mentioned in definitive agreements.

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380

g)	Nature of consideration - whether cash consideration or share swap and details of the same;	Cash Consideration.
h)	Cost of acquisition or the price at which the shares are acquired	In accordance with the definitive agreements, Cipla would invest an amount of Rs. 25 crore (approx.) for acquisition / subscription of 21.05% stake in Achira on a fully diluted basis in the following manner:
i)	Percentage of shareholding / control acquired and / or number of shares acquired;	<ol style="list-style-type: none"> 1. Subscription of 9,28,874 Series C Compulsorily Convertible Preference shares of face value Rs. 10 per share; 2. Acquisition of 1,04,075 Compulsorily Convertible Preference Shares of face value Rs. 10 per share; and 3. Acquisition of 1,04,074 Equity Shares of face value of Re. 1 per share.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Achira Labs is an ISO 13485 compliant medical diagnostics company incorporated in Bengaluru, India, developing products using microfluidic technology. Achira aims to bring sophisticated medical tests closer to the point of diagnosis, treatment and management through its innovative solutions and cutting-edge research, by leveraging its state-of-the-art capabilities, strong collaborations and deep expertise.</p> <p>Date of Incorporation: 12th November 2009</p> <p>History of last 3 years turnover: FY 21-22: Rs 13.79 crores (unaudited) FY 20-21: Rs. 2.60 crores FY 19-20: Rs. 0.03 crores</p> <p>Country in which Achira has its presence: India</p>

Cipla Ltd.

Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India

P +91 22 24826000 F +91 22 24826120 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380